Fitzgerald, G. A. and Shipp, E. (1992) Antiplatelet and anticoagulant drugs in coronary vascular disease. Ann Epidemiol.
2(4), 529–542.
|
| |
Gresele, P. and Agnelli, G. (2002) Novel approaches to the treatment of thrombosis. Trends Pharmacol. Sci.
23(1), 25–32.
|
| |
Hirsh, J. (1996) New antithrombotics for the treatment of acute and chronic arterial ischemia. Vasc. Med.
1(1), 72–78.
|
| |
Hirsh, J. and Weitz, J. I. (1999) New antithrombotic agents. Lancet
353(9162), 1431–1436.
|
| |
Leadley, R. J. Jr., Chi, L., Rebello, S. S., and Gagnon, A. (2000) Contribution of in vivo models of thrombosis to the discovery
and development of novel antithrombotic agents. J. Pharmacol. Toxicol. Methods
43(2), 101–116.
|
| |
Radziwon, P., Boczkowska-Radziwon, B., Giedrojc, J., Schenk, J., Wojtukiewicz, M. Z., Kloczko, J., et al. (1998) Effects of
polysulfonate derivative (GL 522-Y-1) on coagulation in vitro and thrombosis in vivo. Haemostasis
28(2), 86–92.
|
| |
Verstraete, M. (1995) New developments in antiplatelet and antithrombotic therapy. Eur. Heart J.
16(Suppl. L), 16–23.
|
| |
Vivekananthan, D. P. and Moliterno, D. J. (2002) Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction:
tailoring therapies to optimize outcome. J. Thromb. Thrombolysis
13(1), 35–39.
|
| |
| Vivekananthan, D. P., Patel, V. B., and Moliterno, D. J. Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute
myocardial infarction. J. Interv. Cardiol.
15(2), 131–139.
|
| |
Weitz, J. and Hirsh, J. (1993) New anticoagulant strategies. J. Lab. Clin. Med.
122(4), 364–373.
|
| |
Loading...